CL2007002617A1 - Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. - Google Patents

Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.

Info

Publication number: CL2007002617A1
Authority: CL; Chile
Prior art keywords: compounds; pirazin; manto; pirrolo; ilo
Prior art date: 2006-09-11

Application number

CL200702617A

Other languages

English (en)

Inventor

Timothy A Eynott Paul Gillespy

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-11

Filing date

2007-09-10

Publication date

2008-05-16

2007-09-10 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2008-05-16 Publication of CL2007002617A1 publication Critical patent/CL2007002617A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CL200702617A 2006-09-11 2007-09-10 Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. CL2007002617A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US82516806P	2006-09-11	2006-09-11

Publications (1)

Publication Number	Publication Date
CL2007002617A1 true CL2007002617A1 (es)	2008-05-16

Family

ID=39032357

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200702617A CL2007002617A1 (es)	2006-09-11	2007-09-10	Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.

Country Status (32)

Country	Link
US (2)	US8658649B2 (es)
EP (1)	EP2094708B1 (es)
JP (1)	JP5161237B2 (es)
KR (1)	KR101443056B1 (es)
CN (2)	CN103804383A (es)
AR (1)	AR062745A1 (es)
AU (1)	AU2007296592B8 (es)
BR (1)	BRPI0716781A2 (es)
CA (1)	CA2663175C (es)
CL (1)	CL2007002617A1 (es)
CO (1)	CO6160236A2 (es)
CR (1)	CR10636A (es)
DK (1)	DK2094708T3 (es)
ES (1)	ES2437318T3 (es)
GT (1)	GT200900055A (es)
HN (1)	HN2009000455A (es)
IL (1)	IL197381A (es)
MA (1)	MA30781B1 (es)
MX (1)	MX2009002616A (es)
MY (1)	MY148107A (es)
NI (1)	NI200900021A (es)
NO (1)	NO20091265L (es)
NZ (1)	NZ575496A (es)
PE (1)	PE20081372A1 (es)
PT (1)	PT2094708E (es)
RU (1)	RU2440352C2 (es)
TN (2)	TN2009000050A1 (es)
TW (1)	TWI399379B (es)
UA (1)	UA94622C2 (es)
UY (1)	UY30584A1 (es)
WO (1)	WO2008033798A2 (es)
ZA (1)	ZA200901073B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2712507A1 (en)	2008-02-25	2009-09-03	F. Hoffmann-La Roche Ag	Pyrrolopyrazine kinase inhibitors
EP2247595B1 (en)	2008-02-25	2011-07-20	F. Hoffmann-La Roche AG	Pyrrolopyrazine kinase inhibitors
EP2245033B1 (en) *	2008-02-25	2011-08-31	F. Hoffmann-La Roche AG	Pyrrolopyrazine kinase inhibitors
RU2010139284A (ru)	2008-02-25	2012-04-10	Ф.Хоффманн-Ля Рош Аг (Ch)	Пирролопиразины в качестве ингибиторов киназ
PL2247592T3 (pl)	2008-02-25	2012-01-31	Hoffmann La Roche	Pirolopirazynowe inhibitory kinazy
KR20110009084A (ko) *	2008-03-10	2011-01-27	사노피-아벤티스	눈-관련된 장애의 치료방법
FR2929851B1 (fr) *	2008-04-09	2012-11-30	Centre Nat Rech Scient	Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
PA8851701A1 (es)	2008-12-03	2010-07-27	Sanofi Aventis	Tratamiento para la glomerulonefritis
TW201033211A (en)	2008-12-04	2010-09-16	Sanofi Aventis	Crystalline forms
AR074776A1 (es) *	2008-12-18	2011-02-09	Sanofi Aventis	Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
US20110112101A1 (en) *	2009-03-05	2011-05-12	Sanofi-Aventis	Treatment for ocular-related disorders
AR075869A1 (es) *	2009-03-19	2011-05-04	Sanofi Aventis	Sintesis de azaindoles
MA33909B1 (fr)	2009-12-23	2013-01-02	Takeda Pharmaceutical	Pyrrolidinones accoles en tant d'inhibiteurs de syk
US8481541B2 (en)	2010-03-22	2013-07-09	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
US8518945B2 (en)	2010-03-22	2013-08-27	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
EP2571880A1 (en) *	2010-05-20	2013-03-27	F.Hoffmann-La Roche Ag	Pyrrolo [2, 3 - b]pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
MX2012013194A (es)	2010-05-20	2013-01-22	Hoffmann La Roche	Derivados pirrolopirazinas como inhibidores de cinasas tirocina-cinasa del baso (syk) y cinasa de janus (jak).
EP2441755A1 (en)	2010-09-30	2012-04-18	Almirall, S.A.	Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2489663A1 (en)	2011-02-16	2012-08-22	Almirall, S.A.	Compounds as syk kinase inhibitors
EP2723739B1 (en)	2011-06-22	2016-08-24	Takeda Pharmaceutical Company Limited	Substituted 6-aza-isoindolin-1-one derivatives
CA2876543A1 (en) *	2012-08-21	2014-02-27	F. Hoffmann-La Roche Ag	Pyrrolo[2,3-b]pyrazines as syk inhibitors
WO2015017610A1 (en) *	2013-07-31	2015-02-05	Gilead Sciences, Inc.	Syk inhibitors
BR112021018168B1 (pt)	2019-03-21	2023-11-28	Onxeo	Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
US20220401436A1 (en)	2019-11-08	2022-12-22	INSERM (Institute National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CN116969927B (zh) *	2023-06-07	2024-03-19	中南民族大学	一种从荜茇中提取分离的化合物及该化合物在制备抗炎药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1141949A (en) *	1966-02-23	1969-02-05	Sterling Drug Inc	7-azaindole derivatives
US3992392A (en) *	1973-04-27	1976-11-16	The Ohio State University Research Foundation	Synthesis of indoles from anilines and intermediates therein
SE9100920D0 (sv)	1991-03-27	1991-03-27	Astra Ab	New active compounds
US6075037A (en)	1994-06-09	2000-06-13	Smithkline Beecham Corporation	Endothelin receptor antagonists
FR2732969B1 (fr) *	1995-04-14	1997-05-16	Adir	Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6180643B1 (en)	1996-11-19	2001-01-30	Amgen Inc.	Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
US6312835B1 (en)	1997-02-13	2001-11-06	Queen's University At Kingston	Luminescent compounds and methods of making and using same
NZ337529A (en)	1997-03-19	2000-10-27	Basf Ag	Pyrrolo[2,3-d]pyrimidine derivatives useful as tyrosine kinase inhibitors
WO1998047899A1 (en)	1997-04-24	1998-10-29	Ortho-Mcneil Corporation, Inc.	Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
EA200000098A1 (ru)	1997-08-05	2000-08-28	Пфайзер Продактс Инк.	4-АМИНОПИРРОЛ(3,2-d)ПИРИМИДИНЫ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА НЕЙРОПЕПТИДА Y
ATE267200T1 (de)	1997-10-20	2004-06-15	Hoffmann La Roche	Bicyclische kinase inhibitoren
CA2322487C (en)	1998-03-06	2010-07-20	Metabasis Therapeutics, Inc.	Novel prodrugs for phosphorus-containing compounds
CA2326140A1 (en)	1998-04-02	1999-10-14	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
EP1067931A1 (en)	1998-04-02	2001-01-17	Merck & Co., Inc. (a New Jersey corp.)	Antagonists of gonadotropin releasing hormone
US6673797B1 (en)	1998-05-26	2004-01-06	Chugai Seiyaku Kabushiki Kaisha	Heterocyclic indole derivatives and mono- or diazaindole derivatives
JP2002527359A (ja)	1998-09-18	2002-08-27	ビーエーエスエフアクチェンゲゼルシャフト	キナーゼインヒビターとしての４−アミノピロリピリミジン
PE20010306A1 (es)	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
MXPA02006338A (es)	1999-12-24	2002-12-13	Aventis Pharma Ltd	Azaindoles.
GB9930698D0 (en) *	1999-12-24	2000-02-16	Rhone Poulenc Rorer Ltd	Chemical compounds
US6770666B2 (en) *	1999-12-27	2004-08-03	Japan Tobacco Inc.	Fused-ring compounds and use thereof as drugs
YU54202A (sh)	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
DE10009000A1 (de) *	2000-02-25	2001-08-30	Basf Ag	Verfahren zur Herstellung substituierter Indole
AU2001247589A1 (en) *	2000-03-20	2001-10-03	Axys Pharmaceuticals, Inc.	Non-amidine containing protease inhibitors
JP2001302667A (ja) *	2000-04-28	2001-10-31	Bayer Ag	イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6673923B2 (en) *	2000-05-03	2004-01-06	Tularik Inc.	Pyrazole antimicrobial agents
MXPA02010763A (es)	2000-06-14	2003-03-10	Warner Lambert Co	Heterociclicos biciclos-6,5 fusionados.
WO2002028831A1 (en)	2000-10-02	2002-04-11	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
GB0115109D0 (en) *	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
WO2003000690A1 (en)	2001-06-25	2003-01-03	Aventis Pharmaceuticals Inc.	Synthesis of heterocyclic compounds employing microwave technology
AR035543A1 (es)	2001-06-26	2004-06-16	Japan Tobacco Inc	Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
EP1441725A1 (en)	2001-10-26	2004-08-04	Aventis Pharmaceuticals Inc.	Benzimidazoles and analogues and their use as protein kinases inhibitors
US20040082365A1 (en) *	2002-07-18	2004-04-29	Celerica Ltd	Digitization and transmitting cellular RF signals by several light wavelengths
EP1388541A1 (en)	2002-08-09	2004-02-11	Centre National De La Recherche Scientifique (Cnrs)	Pyrrolopyrazines as kinase inhibitors
WO2005014543A1 (ja)	2003-08-06	2005-02-17	Japan Tobacco Inc.	縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
WO2006015124A2 (en) *	2004-07-27	2006-02-09	Sgx Pharmaceuticals, Inc.	Fused ring heterocycle kinase modulators
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
FR2876582B1 (fr)	2004-10-15	2007-01-05	Centre Nat Rech Scient Cnrse	Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
KR20070074610A (ko)	2004-11-08	2007-07-12	백스터 인터내셔널 인코포레이티드	튜불린 억제제의 나노미립자 조성물
KR20070089201A (ko) *	2004-11-22	2007-08-30	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제 억제제로서 유용한 피롤로피라진 및피라졸로피라진
US20110112101A1 (en) *	2009-03-05	2011-05-12	Sanofi-Aventis	Treatment for ocular-related disorders

2007
- 2007-09-10 CL CL200702617A patent/CL2007002617A1/es unknown
- 2007-09-11 CA CA2663175A patent/CA2663175C/en not_active Expired - Fee Related
- 2007-09-11 RU RU2009113615/04A patent/RU2440352C2/ru not_active IP Right Cessation
- 2007-09-11 PT PT78422078T patent/PT2094708E/pt unknown
- 2007-09-11 TW TW096133786A patent/TWI399379B/zh not_active IP Right Cessation
- 2007-09-11 EP EP07842207.8A patent/EP2094708B1/en active Active
- 2007-09-11 CN CN201310652393.XA patent/CN103804383A/zh active Pending
- 2007-09-11 AU AU2007296592A patent/AU2007296592B8/en not_active Ceased
- 2007-09-11 BR BRPI0716781-4A2A patent/BRPI0716781A2/pt not_active IP Right Cessation
- 2007-09-11 JP JP2009538434A patent/JP5161237B2/ja not_active Expired - Fee Related
- 2007-09-11 DK DK07842207.8T patent/DK2094708T3/da active
- 2007-09-11 PE PE2007001220A patent/PE20081372A1/es not_active Application Discontinuation
- 2007-09-11 WO PCT/US2007/078103 patent/WO2008033798A2/en active Search and Examination
- 2007-09-11 ES ES07842207.8T patent/ES2437318T3/es active Active
- 2007-09-11 KR KR1020097005040A patent/KR101443056B1/ko not_active IP Right Cessation
- 2007-09-11 AR ARP070104013A patent/AR062745A1/es not_active Application Discontinuation
- 2007-09-11 CN CNA2007800336608A patent/CN101511838A/zh active Pending
- 2007-09-11 MY MYPI20090720A patent/MY148107A/en unknown
- 2007-09-11 MX MX2009002616A patent/MX2009002616A/es active IP Right Grant
- 2007-09-11 UY UY30584A patent/UY30584A1/es not_active Application Discontinuation
- 2007-09-11 NZ NZ575496A patent/NZ575496A/en not_active IP Right Cessation
- 2007-11-09 UA UAA200903417A patent/UA94622C2/ru unknown
2009
- 2009-02-16 ZA ZA2009/01073A patent/ZA200901073B/en unknown
- 2009-02-17 TN TN2009000050A patent/TN2009000050A1/fr unknown
- 2009-02-17 TN TN2009000049A patent/TN2009000049A1/fr unknown
- 2009-02-17 NI NI200900021A patent/NI200900021A/es unknown
- 2009-02-25 CR CR10636A patent/CR10636A/es not_active Application Discontinuation
- 2009-03-03 IL IL197381A patent/IL197381A/en not_active IP Right Cessation
- 2009-03-10 HN HN2009000455A patent/HN2009000455A/es unknown
- 2009-03-10 US US12/401,254 patent/US8658649B2/en not_active Expired - Fee Related
- 2009-03-10 GT GT200900055A patent/GT200900055A/es unknown
- 2009-03-11 CO CO09025278A patent/CO6160236A2/es unknown
- 2009-03-26 NO NO20091265A patent/NO20091265L/no not_active Application Discontinuation
- 2009-04-06 MA MA31765A patent/MA30781B1/fr unknown
2014
- 2014-01-28 US US14/166,396 patent/US20140142110A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MX2009002616A (es)	2009-03-24
BRPI0716781A2 (pt)	2014-11-18
PT2094708E (pt)	2014-01-07
RU2440352C2 (ru)	2012-01-20
ZA200901073B (en)	2009-12-30
IL197381A (en)	2013-11-28
CR10636A (es)	2009-03-20
NO20091265L (no)	2009-04-03
UA94622C2 (en)	2011-05-25
AU2007296592A1 (en)	2008-03-20
TN2009000049A1 (en)	2010-08-19
PE20081372A1 (es)	2008-11-27
NZ575496A (en)	2011-09-30
WO2008033798A2 (en)	2008-03-20
CN101511838A (zh)	2009-08-19
MA30781B1 (fr)	2009-10-01
JP5161237B2 (ja)	2013-03-13
DK2094708T3 (da)	2014-01-27
ES2437318T3 (es)	2014-01-10
US8658649B2 (en)	2014-02-25
GT200900055A (es)	2010-07-28
US20100035884A1 (en)	2010-02-11
MY148107A (en)	2013-02-28
AU2007296592B8 (en)	2012-01-12
RU2009113615A (ru)	2010-10-20
UY30584A1 (es)	2008-05-02
TN2009000050A1 (en)	2010-08-19
AR062745A1 (es)	2008-12-03
TWI399379B (zh)	2013-06-21
IL197381A0 (en)	2009-12-24
JP2010502767A (ja)	2010-01-28
CA2663175A1 (en)	2008-03-20
TW200829590A (en)	2008-07-16
NI200900021A (es)	2010-01-29
WO2008033798A3 (en)	2008-05-15
EP2094708A2 (en)	2009-09-02
US20140142110A1 (en)	2014-05-22
AU2007296592B2 (en)	2011-12-15
HN2009000455A (es)	2012-02-13
EP2094708B1 (en)	2013-10-23
CO6160236A2 (es)	2010-05-20
KR101443056B1 (ko)	2014-09-22
CN103804383A (zh)	2014-05-21
CA2663175C (en)	2012-03-13
KR20090063214A (ko)	2009-06-17

Publication	Publication Date	Title
CL2007002617A1 (es)	2008-05-16	Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
CL2007002682A1 (es)	2008-04-04	Compuestos derivados de 4-metilpiridopirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el crecimiento anormal de celulas, como cancer.
CL2007003774A1 (es)	2008-04-18	Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
CL2007003202A1 (es)	2008-03-07	Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2008000197A1 (es)	2008-08-01	Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2007003226A1 (es)	2008-02-08	Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
CL2012001627A1 (es)	2012-10-05	Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer.
CL2010001637A1 (es)	2011-07-15	Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
CL2007003244A1 (es)	2008-04-04	Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2008000754A1 (es)	2008-10-24	Compuesto derivado de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar cancer y trastornos hiperproliferativos.
CL2007003520A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2008002319A1 (es)	2009-01-02	Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2007003666A1 (es)	2008-07-04	Compuestos derivados del acido nicotinico; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis, esclerosis multiple, psoriasis, entre otras.
CL2008000703A1 (es)	2008-09-26	Compuestos derivados de pirimidinas sustituidas; procedimiento para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar transtornos hematologicos.
CL2008000825A1 (es)	2008-11-03	Compuestos heterociclicos derivados de quinolincarboxamidas utiles como antagonistas de p2x7; su metodo de preparacion; la composicion farmaceutica que lo contiene; el emtodo de preparacion de la composicion; y el uso de los mismos para preparar medicamentos utiles en artritis reumatoide.
CL2011000527A1 (es)	2011-08-12	Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
CL2007003138A1 (es)	2008-06-27	Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2008001633A1 (es)	2008-12-12	Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2009000447A1 (es)	2010-01-04	Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf.
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
CL2007002377A1 (es)	2008-04-04	Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
CL2007000161A1 (es)	2008-05-30	Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2007002330A1 (es)	2008-02-15	Compuestos derivados de oxo aza antraceno; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el rechazo de trasplante, artritis reumatoide, artritis psoriatica, esclerosis multiple, asma, entre otras.
CL2007002856A1 (es)	2008-01-18	Compuestos derivados de pirazolo(1,5)pirimidina; composicion farmaceutica qu lo comprende;y su uso para tratar el cancer.
CL2008000029A1 (es)	2008-04-04	Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.